Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases

Bonnet et al., Frontiers in Medicine, doi:10.3389/fmed.2024.1305184
Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
26th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Review of clinical studies on the potential benefits of antidepressants for prevention and treatment of COVID-19 and its sequelae. Authors summarize evidence from retrospective studies, randomized controlled trials, prospective studies, and meta-analyses suggesting that antidepressants, especially selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, may help prevent SARS-CoV-2 infection, reduce COVID-19 severity and mortality, and potentially alleviate long COVID symptoms. Proposed mechanisms include direct antiviral effects and anti-inflammatory properties. Authors make a case for considering inexpensive and available antidepressants as adjunctive therapy, emphasizing their affordability and availability.
Reviews covering fluvoxamine for COVID-19 include Hashimoto, Hashimoto (B), Hashimoto (C), Hoertel, Kirsch, Sukhatme.
Bonnet et al., 20 Feb 2024, peer-reviewed, 3 authors.
This PaperFluvoxamineAll
Abstract: TYPE Opinion PUBLISHED 20 February 2024 DOI 10.3389/fmed.2024.1305184 OPEN ACCESS EDITED BY Daniel Diaz, National Autonomous University of Mexico, Mexico REVIEWED BY Velyn Wu, University of Florida, United States *CORRESPONDENCE Udo Bonnet udo.bonnet@uni-due.de RECEIVED 17 December 2023 ACCEPTED 05 February 2024 PUBLISHED 20 February 2024 CITATION Bonnet U, Juckel G and Kuhn J (2024) Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases. Front. Med. 11:1305184. doi: 10.3389/fmed.2024.1305184 Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases Udo Bonnet1,2*, Georg Juckel3 and Jens Kuhn4,5 1 Department of Mental Health, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany, 2 Department of Psychiatry and Psychotherapy, Faculty of Medicine, Landschaftsverband Rheinland-Hospital Essen, University of Duisburg-Essen, Essen, Germany, 3 Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr University Bochum, Bochum, Germany, 4 Department of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany, 5 Alexianer Hospital Cologne, Cologne, Germany KEYWORDS antidepressants, resilience, prevention, COVID-19, Long COVID, Post COVID, PACS COPYRIGHT © 2024 Bonnet, Juckel and Kuhn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit